Human malignancies progress using uncontrolled transduction pathways. Molecules (like VEGF for example) bind to membrane receptors that stimulate transduction pathways (like RAS/MEK/ERK) and activate or inhibit the production of cytoplasmic proteins. Thus it is possible to define targets which can be receptors, molecules or proteins and consequently develop active drugs for targeted therapy.